Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Mismatch Negativity and P50 Sensory Gating in Abstinent Former Cannabis Users.

Broyd SJ, Greenwood LM, van Hell HH, Croft RJ, Coyle H, Lee-Bates B, Todd J, Johnstone SJ, Michie PT, Solowij N.

Neural Plast. 2016;2016:6526437. doi: 10.1155/2016/6526437. Epub 2016 Feb 25.

2.

Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.

Xie J, Xiao D, Xu Y, Zhao J, Jiang L, Hu X, Zhang Y, Yu L.

Oncotarget. 2016 Feb 9;7(6):6436-47. doi: 10.18632/oncotarget.7042.

3.

Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.

Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, Gao H, Labaree D, Neumeister A, Pittman B, Surti T, Huang Y, Carson RE, D'Souza DC.

Biol Psychiatry. 2016 Jun 15;79(12):997-1005. doi: 10.1016/j.biopsych.2015.08.021. Epub 2015 Aug 29.

PMID:
26432420
4.

Cannabis and psychopathology: The meandering journey of the last decade.

Ghosh A, Basu D.

Indian J Psychiatry. 2015 Apr-Jun;57(2):140-9. doi: 10.4103/0019-5545.158134. Review.

5.

Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis.

Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A, Taurisano P, Romano R, Masellis R, Blasi G, Morgan C, Aitchison K, Mondelli V, Luzi S, Kolliakou A, David A, Murray RM, Bertolino A, Di Forti M.

Schizophr Bull. 2015 Sep;41(5):1171-82. doi: 10.1093/schbul/sbv032. Epub 2015 Mar 31.

PMID:
25829376
6.

Crude estimates of cannabis-attributable mortality and morbidity in Canada-implications for public health focused intervention priorities.

Fischer B, Imtiaz S, Rudzinski K, Rehm J.

J Public Health (Oxf). 2016 Mar;38(1):183-8. doi: 10.1093/pubmed/fdv005. Epub 2015 Jan 28.

PMID:
25630540
7.

Hemispheric language asymmetry in first episode psychosis and schizotypy: the role of cannabis consumption and cognitive disorganization.

Herzig DA, Sullivan S, Lewis G, Corcoran R, Drake R, Evans J, Nutt D, Mohr C.

Schizophr Bull. 2015 Mar;41 Suppl 2:S455-64. doi: 10.1093/schbul/sbu179. Epub 2014 Dec 27.

8.

Increasing endocannabinoid levels in the ventral pallidum restore aberrant dopamine neuron activity in the subchronic PCP rodent model of schizophrenia.

Aguilar DD, Chen L, Lodge DJ.

Int J Neuropsychopharmacol. 2014 Oct 31;18(1). pii: pyu035. doi: 10.1093/ijnp/pyu035.

9.

Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis.

Nottage JF, Stone J, Murray RM, Sumich A, Bramon-Bosch E, Ffytche D, Morrison PD.

Psychopharmacology (Berl). 2015 Feb;232(3):519-28. doi: 10.1007/s00213-014-3684-1. Epub 2014 Jul 20.

10.

Epigenetics, stress, and their potential impact on brain network function: a focus on the schizophrenia diatheses.

Diwadkar VA, Bustamante A, Rai H, Uddin M.

Front Psychiatry. 2014 Jun 23;5:71. doi: 10.3389/fpsyt.2014.00071. eCollection 2014. Review.

11.

Gone to Pot - A Review of the Association between Cannabis and Psychosis.

Radhakrishnan R, Wilkinson ST, D'Souza DC.

Front Psychiatry. 2014 May 22;5:54. doi: 10.3389/fpsyt.2014.00054. eCollection 2014. Review.

12.

Clearing the smoke: what do we know about adolescent cannabis use and schizophrenia?

Hill MN.

J Psychiatry Neurosci. 2014 Mar;39(2):75-7. No abstract available.

13.

Cannabis and psychosis: Neurobiology.

Shrivastava A, Johnston M, Terpstra K, Bureau Y.

Indian J Psychiatry. 2014 Jan;56(1):8-16. doi: 10.4103/0019-5545.124708. Review.

14.

Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain.

Levin R, Peres FF, Almeida V, Calzavara MB, Zuardi AW, Hallak JE, Crippa JA, Abílio VC.

Front Pharmacol. 2014 Feb 6;5:10. doi: 10.3389/fphar.2014.00010. eCollection 2014.

15.

Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones.

Khullar V, Jain A, Sattari M.

J Gen Intern Med. 2014 Aug;29(8):1200-4. doi: 10.1007/s11606-014-2802-4. Epub 2014 Feb 20. Review.

16.

Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects.

Smith MJ, Cobia DJ, Wang L, Alpert KI, Cronenwett WJ, Goldman MB, Mamah D, Barch DM, Breiter HC, Csernansky JG.

Schizophr Bull. 2014 Mar;40(2):287-99. doi: 10.1093/schbul/sbt176. Epub 2013 Dec 15.

17.

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Porter BE, Jacobson C.

Epilepsy Behav. 2013 Dec;29(3):574-7. doi: 10.1016/j.yebeh.2013.08.037.

18.

Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.

Davis GP, Compton MT, Wang S, Levin FR, Blanco C.

Schizophr Res. 2013 Dec;151(1-3):197-202. doi: 10.1016/j.schres.2013.10.018. Epub 2013 Nov 5.

19.

Does Cannabidiol Protect Against Adverse Psychological Effects of THC?

Niesink RJ, van Laar MW.

Front Psychiatry. 2013 Oct 16;4:130. doi: 10.3389/fpsyt.2013.00130. Review.

20.

Cannabis, a complex plant: different compounds and different effects on individuals.

Atakan Z.

Ther Adv Psychopharmacol. 2012 Dec;2(6):241-54. doi: 10.1177/2045125312457586.

Items per page

Supplemental Content

Write to the Help Desk